Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

NanoViricides, Inc.

  • Anil Diwan, NanoViricides, Inc.

NanoViricides, Inc. is pioneering a unique platform of nanomedicines to treat viral diseases that we call nanoviricides®. We are advancing our first drug candidate in the HerpeCide™ program towards clinical trials. The initial indication would be for topical treatment of shingles rash. Additional drugs against HSV-1 cold sores and HSV-2 genital ulcers would follow. The Company has previously demonstrated drug candidates with strong efficacy in animal studies against a wide range of viruses including Influenzas, HIV, Dengue, Ebola, among others, attesting to robustness of the platform. The Company is also unique in that it has its own flexible multi-product c-GMP-capable manufacturing facility that can scale to several kg API per batch, enabling rapid translation to the clinic. Our platform is designed to mimic host cell receptors to the virus, thereby trapping & destroying the virus particle. This approach makes viral resistance unlikely as the resistant virus would be incompetent.

  • Date:Tuesday, February 12
  • Time:2:30 PM - 2:45 PM
  • Room:Gramercy
  • Location:7th Floor
  • Session Type:Company Presentation
  • Submission ID:23599
  • Company Presentation - Presentation Type:Publicly Traded Company
  • Goal for Presentation:Investor outreach
  • Company Website:www.nanoviricides.com
  • Company HQ City:Shelton
  • Company HQ State:Connecticut
  • Company HQ Country:United States
  • Market Cap:$25MM
  • Ticker:NNVC
  • Exchange:NYSE-American
  • CEO/Top Company Official:Anil R. Diwan
  • Year Founded:2005
  • Main Therapeutic Focus:Infectious Diseases
  • Lead Product in Development:NV-VZV-101
  • Development Phase of Primary Product:Pre-Clinical
  • Number Of Unlicensed Products (For Which You Are Seeking Partners):3+
  • Additional Information/Comments:Platform technology. Zip-code like delivery to virus particles and to infected cells that express viral glycoprotein. The targeted polymer itself is the drug against enveloped viruses, designed to block reinfection. Additional APIs to block replication cycle can be encapsulated readily to completely block virus lifecycle.
Speakers
Anil Diwan
NanoViricides, Inc.
Back